Biogen released Long-Term Clinical Results of Antibody Therapy for Alzheimer’s Disease
- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
Biogen released Long-Term Clinical Results of Antibody Therapy for Alzheimer’s Disease
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
Biogen released Long-Term Clinical Results of Antibody Therapy for Alzheimer’s Disease
On March 17, Biogen announced that the latest data showed that after nearly two and a half years (128 weeks) of treatment with the anti-amyloid beta (Aβ) monoclonal antibody Aduhelm (aducanumab-avwa), two Phase 3 The key pathological features of Alzheimer’s disease — Aβ deposition and plasma p-tau181 levels — consistently decreased significantly in patients in the clinical trial.
At 78 weeks of treatment, patients with reduced plasma p-tau181 levels had less cognitive decline than patients with no change in p-tau181 levels.
The company also announced that Aduhelm’s Phase 3 clinical trial data were published in The Journal of Prevention of Alzheimer’s Disease.
Aduhelm is an anti-Aβ monoclonal antibody jointly developed by Biogen and Eisai, which promotes the elimination of Aβ deposits in the brain by binding to Aβ in Aβ deposits. It received accelerated approval from the U.S. FDA last year for the treatment of patients with early-stage Alzheimer’s disease.
The data reported this time includes open-label, extended-phase data from two Phase 3 clinical trials, EMERGE and ENGAGE. The data showed that Aduhelm continued to reduce Aβ levels in the patients’ brains after two years of treatment.
Image source: Biogen official website
In addition, Aduhelm continued to reduce plasma p-tau181 levels in patients after two years of treatment. Patients with more effective clearance of Aβ deposits also had greater reductions in p-tau181 levels at 128 weeks.
In two phase 3 clinical trials, patients with reduced plasma p-tau181 levels after 78 weeks of treatment, as assessed by 4 different assays (CDR-SB, MMSE, ADAS-Cog13, and ADCS-ADL-MCI) Disease progression is also slower.
References:
[1] Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease. Retrieved March 16, 2022, from https://investors.biogen.com/news-releases/news-release-details/biogen-announces-peer-reviewed-publication-aduhelmr-phase-3
[2] Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years. Retrieved March 16, 2022, from https://investors.biogen.com/news-releases/news-release-details/long-term-phase-3-data-show-aduhelmr-continues-reduce-underlying
[3] Key Milestones in Alzheimer’s Disease. Retrieved March 16, 2022, from https://investors.biogen.com/static-files/3cce2949-6846-45b0-b34c-1187445cfd9d
Biogen released Long-Term Clinical Results of Antibody Therapy for Alzheimer’s Disease
(source:internet, reference only)
Disclaimer of medicaltrend.org
